Exosome & EV CDMOs — Ranked by Signal Score · 2026
Exosome / Extracellular Vesicle manufacturers on CDMO Signal: 6 listed, 6 with a Signal Score. Fewer than three are fully evidenced (all four score pillars and at least one ClinicalTrials.gov match), so this page does not name a top three. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-10-16. Methodology.
Exosome and extracellular vesicle (EV) CDMOs manufacture next-generation delivery vehicles for RNA, proteins, and small molecules. As an emerging modality, the field is still standardizing cell-source, isolation, and potency methods.
Choosing an exosome CDMO turns on cell-source and culture scale, isolation method (TFF, chromatography), characterization, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
Last updated 2026-10-16. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score
Showing contract manufacturers only.
| # | CDMO | Signal Score | Quality | FDA · GMP | Last FDA inspection | Capacity | Programs |
|---|---|---|---|---|---|---|---|
| 1 |
EA
Singapore, Singapore
|
63.0 | — | — | None on file | — | — |
| 2 |
CK
|
60.3 | — | — | None on file | — | 16 programs |
| 3 |
EXO
Liège, Belgium
|
56.5 | — | — | None on file | — | — |
| 4 |
EV
|
56.5 | — | — | None on file | — | — |
| 5 |
EP
Melbourne, Australia
|
56.5 | — | — | None on file | — | — |